Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PREP | P48147 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16142834 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AFKBP1ANPSR1 | |
| SCHEMBL29302827 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AFKBP1ANPSR1 | |
| SCHEMBL23270785 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AFKBP1ANPSR1 | |
| SCHEMBL1515645 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9AFKBP1ANPSR1 | |
| SCHEMBL19592114 | 0.91 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ANPSR1PREP | |
| SCHEMBL2678862 | 0.91 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ANPSR1PREP | |
| SCHEMBL19234258 | 0.91 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ANPSR1PREP | |
| Hydrochloric Acid SCHEMBL5409774 | 0.90 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ANPSR1PREP | |
| SCHEMBL29613583 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ANPSR1PREP | |
| SCHEMBL820518 | 0.89 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ANPSR1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727552-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259310-A2 | PASSIVE PERMEABLE PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| EP-3810129-B1 | PCSK9 ANTAGONIST BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | MERCK SHARP & DOHME CORP. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-07-15 | — | — | US | disclosed |
| WO-2021127460-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021041770-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-9999625-B2 | Pyrrolobenzodiazepine compounds | FEMTOGENIX LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170050971-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | US | disclosed |
| WO-2015166289-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2015-11-05 | — | — | WO | disclosed |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2009137130-A2 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | ACHAOGEN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-0646595-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1998-11-04 | — | — | EP | disclosed |
| US-5623049-A | FLEXIBLE ANTISENSE AGENTS COMPRISING OLIGONUCEOTIDES HAVING THE (DEOXY)RIBOSE BACKBONE REPLACED BY AN OLIGOPEPTIDE; PROTEASE- AND NUCLEASE-RESISTANT; VIRICIDES; ATTACHED TO CARRIERS ABLE TO PENETRATATE IN CELLS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0646595-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214395-A1 | PCSK9 ANTAGONISTS BICYCLO-COMPOUNDS | PCSK9, PCSK7, PCSK6 | SMN1; SMN2 4541/4885NPC1 100/4885RAB9A 691/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | SMN1; SMN2 3778/4885NPC1 82/4885RAB9A 1128/4885 |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | SMN1; SMN2 4322/4885NPC1 121/4885RAB9A 589/4885 |
| US-11306125-B2 | PCSK9 antagonists bicyclo-compounds | PCSK9, PCSK7, PCSK6 | SMN1; SMN2 4541/4885NPC1 100/4885RAB9A 691/4885 |
| US-20170050971-A1 | PYRROLOBENZODIAZEPINE COMPOUNDS | DRD1, DRD2, DRD3 | SMN1; SMN2 4005/4885NPC1 3617/4885RAB9A 825/4885 |
| US-20120058989-A1 | ANTIBACTERIAL FLUOROQUINOLONE ANALOGS | RECQL, BLVRB, NQO2 | SMN1; SMN2 3896/4885NPC1 2857/4885RAB9A 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.